MSP-00822 is under clinical development by Sathgen Biotech and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MSP-00822’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MSP-00822 overview
MSP-00822 is under development for the treatment of breast cancer including triple negative breast cancer, malignant neoplasm, metastatic ovarian cancer, head and neck squamous cell carcinoma, metastatic prostate cancer and coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome virus 2 (SARS-CoV-2). It is new chemical entity (NCE). It is administered through oral route.
Sathgen Biotech overview
Sathgen Biotech is an anti-cancer drug screening laboratory with focus on the design, synthesis and analysis of small molecules that inhibit cancer and cancer stem cells. It operates a research and development facility where it carries out anti-cancer drug screening using innovative methods. Its pipeline product portfolio includes proprietary compounds such as SBGB-0001-000, SBGB-0001-001, SBGB-0012-000, SBGB-0013-000, SBGB-0014-000, SBGB-0003-000, and SBGB-0004-000 targeting breast and prostate cancers. It developed a sphere assay to measure cancer stem cell (CSC) properties and screen small molecules for developing anti- CSC-specific therapies. Sathgen Biotech also provides in vitro drug screening service to other R&D companies. Sathgen Biotech is the cancer research and development division of Godavari Biorefineries Ltd. Sathgen Biotech is headquartered in Mumbai, Maharashtra, India.
For a complete picture of MSP-00822’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
